



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Innovax-ILT Concentrate and Solvent for Suspension for Injection for Chickens

Vm 01708/5039

08 March 2026	Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex.
28 November 2025	To delete a site for antigen production, in process control testing, blending, primary packaging and secondary packaging.
16 November 2023	Harmonise the storage conditions of the vaccine concentrate with that of other Innovax vaccines. Align the product information with the current QRD template version.
06 April 2022	Align the product information with the current QRD template version.
27 January 2022	Change in the number of units in a pack within the range of the currently approved pack sizes of the finished product. Deletion of manufacturing site. Deletion of manufacturing site. Change in the number of units in a pack outside the range of the currently approved pack sizes of the finished product. Increase in the shelf-life of the finished product as packaged for sale, from 2 to 3 years. Change in storage conditions of the finished product. Deletion of the solvent container from the pack. Changes in the composition (excipients) of the finished product.
24 March 2021	Change in the address of manufacture of the active substance.
17 March 2021	Change in the address of the manufacturer of the finished product.